7 unknown, 3 completed. 6 Not applicable, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 6 | Unknown 5, Completed 1 |
| Phase 4 | 2 | Completed 2 |
Follow mRNA Vaccines: new trials by email Literature Review of mRNA Vaccines trials Research Report on mRNA Vaccines
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high dose, Placebo - SARS-CoV-2 | Not applicable | Unknown | AIM Vaccine Co., Ltd. | 350 | 2023-04-01 | 2023-03-16 |
| Clinical Trial of COVID-19 Vaccine（SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine） in Participants Aged 18 Years and Over SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine, Saline solution - SARS-CoV-2 | Not applicable | Unknown | AIM Vaccine Co., Ltd. | 3200 | 2023-01-04 | 2023-02-28 |
| Sequential Enhanced Safety Study of a Novel Coronavirus Messenger RNA (mRNA) Vaccine in Adults Aged 18 Years and Older. 0.3ml of mRNA vaccine - Corona Virus Disease 2019(COVID-19) | Not applicable | Unknown | Yu Qin | 800 | 2022-09-21 | 2022-10-06 |
| A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose, Placebo - SARS-CoV-2 | Not applicable | Unknown | AIM Vaccine Co., Ltd. | 54 | 2022-09-16 | 2023-02-14 |
| A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose, COVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose, Placebo - SARS-CoV-2 | Not applicable | Unknown | AIM Vaccine Co., Ltd. | 54 | 2022-09-13 | 2023-02-14 |
| Comparative Evaluation of Covid-19 Vaccines Response Covid-19 Inactive Vaccine, recombinant human adenovirus serotype number 26, mRNA VAccine - COVID-19 Vaccines | Unknown | Karamanoğlu Mehmetbey University | 1500 | 2021-06-01 | 2021-07-15 | |
| SafeTy and Efficacy of Preventative CoVID Vaccines mRNA Vaccines or Viral vector-based vaccines for COVID - COVID-19 Virus Infection, Vaccine Response | Unknown | University Health Network, Toronto | 1286 | 2021-05-06 | 2023-01-05 | |
| COVID-19 Vaccination of Immunodeficient Persons (COVAXID) Comirnaty (COVID-19, mRNA vaccine) - Covid19 | Phase 4 | Completed | Karolinska University Hospital | 539 | 2021-02-23 | 2025-12-04 |
| Novelty, Conformity and Trust in COVID-19 Vaccines RNA vaccine, 20% adoption rate, 40% adoption rate - Trust | Not applicable | Completed | National University of Singapore | 35180 | 2021-02-01 | 2022-02-22 |
| Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients Sarna, Cetaphil - Pruritis | Phase 4 | Completed | Wake Forest University | 28 | 2006-11-01 | 2018-09-10 |
COVID-19 (4) · Coronavirus Infections (1) · Pruritus (1)
AIM Vaccine Co., Ltd. (4) · Karamanoğlu Mehmetbey University (1) · Karolinska University Hospital (1) · National University of Singapore (1) · University Health Network, Toronto (1) · Wake Forest University (1) · Yu Qin (1)
China (4) · United States (2) · Canada (1) · Sweden (1) · Turkey (Türkiye) (1)
Huan Zhou (4) · Qiang Wu (4) · Alan Fleischer, MD (1) · Sharon Walmsley, MD (1) · Soo Aleman, MD, PhD (1) · Teck Ho (1)
PMID 33283264, PMID 35075450, PMID 35135470, PMID 37453361, PMID 38211584, PMID 38903523, PMID 39224811, PMID 39247614, PMID 39395230